|
AstraZeneca wins FDA
breakthrough status for key cancer drug
Send a link to a friend
[February 17, 2016]
LONDON (Reuters) - The U.S. Food and
Drug Administration has granted breakthrough therapy designation to
AstraZeneca's biggest new drug hope durvalumab as a treatment in
bladder cancer, the drugmaker said on Wednesday.
|
|
 The experimental medicine is a so-called PD-L1 therapy that fights
cancer by boosting the immune system.
Breakthrough therapy designation expedites the development and
review of medicines intended to treat serious or life-threatening
diseases.
Durvalumab is also being developed as a treatment for lung, head and
neck, gastric, pancreatic, liver and blood cancers. It faces
competition from rival products made by Bristol-Myers Squibb, Merck
and Roche.
(Reporting by Ben Hirschler; Editing by Mark Potter)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
